• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Polaryx Therapeutics, Inc. - Common Stock (NQ:PLYX)

    2.740 +0.090 (+3.40%)
    Streaming Delayed Price Updated: 1:14 PM EDT, Jul 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 26,465
    Open 2.740
    Bid (Size) 2.710 (1,000)
    Ask (Size) 2.740 (10,000)
    Prev. Close 2.650
    Today's Range 2.650 - 2.830
    52wk Range 2.010 - 48.91
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Why Polaryx Therapeutics Stock Is Surging On Thursday? ↗
    Polaryx Therapeutics (NASDAQ: PLYX) stock climbs on Thursday following a $10M private placement to launch its Phase 2 SOTERIA trial for rare lysosomal storage disorders. 
    Via Benzinga
    News headline image
    Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -92.2%
    -92.2%
    1 Month
    +11.4%
    +11.4%
    3 Month
    -52.2%
    -52.2%
    6 Month
    -92.2%
    -92.2%
    1 Year
    -92.2%
    -92.2%

    More News

    Read More
    Tuesday's session: top gainers and losers ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗
    Via Stocktwits
    Topics ETFs
    News headline image
    Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    What's Going On With Polaryx Therapeutics Stock Wednesday? ↗
    Via Benzinga
    News headline image
    Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans ↗
    Via Benzinga
    News headline image
    Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx Therapeutics Welcomes New Members of the Board of Directors
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
    From Polaryx Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Polaryx Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Polaryx Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Polaryx Therapeutics, Inc. - Common Stock trade on?
    Polaryx Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Polaryx Therapeutics, Inc. - Common Stock?
    The ticker symbol for Polaryx Therapeutics, Inc. - Common Stock is PLYX on the Nasdaq Stock Market
    What is the current price of Polaryx Therapeutics, Inc. - Common Stock?
    The current price of Polaryx Therapeutics, Inc. - Common Stock is 2.740
    When was Polaryx Therapeutics, Inc. - Common Stock last traded?
    The last trade of Polaryx Therapeutics, Inc. - Common Stock was at 07/07/26 01:14 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.